Solpadeine tabletes Latvija - latviešu - Zāļu valsts aģentūra

solpadeine tabletes

perrigo romania srl, romania - paracetamolum, codeini phosphas hemihydricus, kofeīns - tablete - 500 mg/8 mg/30 mg

ellaOne Eiropas Savienība - latviešu - EMA (European Medicines Agency)

ellaone

laboratoire hra pharma - ulipristal - kontracepcija, postcoital - dzimumhormoni un dzimumsistēmas modulatori dzimumorgānu sistēmas, , avārijas kontracepcijas līdzekļi - Ārkārtas kontracepcija 120 stundu laikā (piecās dienās) no neaizsargāta dzimumakta vai kontracepcijas līdzekļa mazspējas.

Vertigoheel tabletes Latvija - latviešu - Zāļu valsts aģentūra

vertigoheel tabletes

biologische heilmittel heel gmbh, germany - conium plankumainas, ambra grisea, un naftas rectificatum, anamirta cocculus - tablete

Dupixent Eiropas Savienība - latviešu - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumabs - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agents for dermatitis, excluding corticosteroids - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Lusopress 20 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

lusopress 20 mg tabletes

istituto luso farmaco d`italia s.p.a., italy - nitrendipīns - tablete - 20 mg

Dostinex 0,5 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

dostinex 0,5 mg tabletes

pfizer europe ma eeig, belgium - kabergolīns - tablete - 0,5 mg

Wakix Eiropas Savienība - latviešu - EMA (European Medicines Agency)

wakix

bioprojet pharma - pitolisant - narkolepsija - other nervous system drugs - wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.

Ozawade Eiropas Savienība - latviešu - EMA (European Medicines Agency)

ozawade

bioprojet pharma - pitolisant - sleep apnea, obstructive - other nervous system drugs - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).

Elfabrio Eiropas Savienība - latviešu - EMA (European Medicines Agency)

elfabrio

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabriku slimība - citas gremošanas trakta un metabolisma produkti, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).